Literature DB >> 11930107

Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent.

P Labarre1, J Papon, M-F Moreau, N Moins, M Bayle, A Veyre, J-C Madelmont.   

Abstract

The cellular uptake and incorporation in macromolecules of iodine-125 labelled N-(2-diethylaminoethyl)-4-iodobenzamide ([125I]BZA), a melanoma imaging agent, was studied using human melanoma cells M3Dau (amelanotic) and M4Beu (melanotic). The interaction between [125I]BZA and synthetic melanin was examined in various conditions of incubation. The results showed that uptake was high only for M4Beu, whereas the incorporation in trichloroacetic acid-precipitable proteins was very low for both model cell lines, with no correlation with melanin content. Experiments with synthetic melanin showed that BZA binding to melanin was saturable and reversible, and involved several types of interaction. The influence of the ionic environment indicated that electrostatic forces play a role in the affinity, and the decrease in binding produced by the presence of an alcohol in the medium suggested that hydrophobic interactions may be involved in the binding mechanism. This was supported by the Scatchard analysis, which revealed two classes of binding sites, and the determination of two association constants (K1 = 3.9 +/- 1.9 x 106/M and K2 = 2.9 +/- 0.9 x 104/M). The affinity of BZA for melanin might explain the good results obtained in a phase II clinical trial for the diagnosis of malignant melanoma metastases, in which the specificity was 100%.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11930107     DOI: 10.1097/00008390-200204000-00003

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  6 in total

1.  Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma.

Authors:  John L Joyal; John A Barrett; John C Marquis; Jianqing Chen; Shawn M Hillier; Kevin P Maresca; Marie Boyd; Kenneth Gage; Sridhar Nimmagadda; James F Kronauge; Matthias Friebe; Ludger Dinkelborg; James B Stubbs; Michael G Stabin; Rob Mairs; Martin G Pomper; John W Babich
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

2.  Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitter.

Authors:  Maryline Gardette; Janine Papon; Mathilde Bonnet; Nicolas Desbois; Pierre Labarre; Ting-Dee Wu; Elisabeth Miot-Noirault; Jean-Claude Madelmont; Jean-Luc Guerquin-Kern; Jean-Michel Chezal; Nicole Moins
Journal:  Invest New Drugs       Date:  2010-06-22       Impact factor: 3.850

3.  Melanin-targeted preclinical PET imaging of melanoma metastasis.

Authors:  Gang Ren; Zheng Miao; Hongguang Liu; Lei Jiang; Naengnoi Limpa-Amara; Ashfaq Mahmood; Sanjiv S Gambhir; Zhen Cheng
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

4.  Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [¹⁰F]ICF01006, a highly promising melanoma PET tracer.

Authors:  Latifa Rbah-Vidal; Aurélien Vidal; Sophie Besse; Florent Cachin; Mathilde Bonnet; Laurent Audin; Serge Askienazy; Frédéric Dollé; Françoise Degoul; Elisabeth Miot-Noirault; Nicole Moins; Philippe Auzeloux; Jean-Michel Chezal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-16       Impact factor: 9.236

Review 5.  Targeting Melanin in Melanoma with Radionuclide Therapy.

Authors:  Kevin J H Allen; Mackenzie E Malo; Rubin Jiao; Ekaterina Dadachova
Journal:  Int J Mol Sci       Date:  2022-08-23       Impact factor: 6.208

6.  Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences.

Authors:  Jean-Luc Guerquin-Kern; François Hillion; Jean-Claude Madelmont; Pierre Labarre; Janine Papon; Alain Croisy
Journal:  Biomed Eng Online       Date:  2004-04-06       Impact factor: 2.819

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.